In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy

Executive Summary

Novartis’ deal with the University of Pennsylvania around cancer immunotherapies based on chimeric antigen receptor technologies developed in the lab of Penn’s Carl June comes at an opportune time. The Big Pharma is fighting to preserve its number two ranking in oncology and Penn’s high-profile, albeit much smaller, alliance with AstraZeneca in neurodegenerative disease is winding down.

Advertisement

Related Content

Tmunity Raises $100m Series A To Fund Next-Gen T-Cell Therapy Trials
Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review
Novartis' CAR-T CTL019 Back On The Blockbuster Hit List
Cell Design Labs Envisions Robot Control of Tomorrow's CAR-T Therapies
Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big
As Sun Sets On Gleevec, Novartis Looks To New Horizons In Oncology
Deals of the Week: AstraZeneca’s Neuroscience Deals, Verastem/Pfizer, Alnylam/Ascletis
AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction
Back To School: Big Pharmas Test New Models For Tapping Academia
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel